Roth Says Use of New Promacta May Provide 'Meaningful' Royalties, EPS Growth to Ligand

An analyst at Roth Capital, Joseph Pantginis, earlier noted Ligand LGND may see EPS growth of up to $0.35 over the next few years, as a result of “meaningful” royalty income from Promacta(R). The product is used to treat persons with severe aplastic anemia (SAA). Pantginis maintains a $69 PT and Buy rating on LGND.